Johnson & Johnson reported 2Q earnings and revenue above estimates due to strong sales of Darzalex and Stelara, and raised 2024 sales forecast to $89.2B-$89.6B.
Johnson & Johnson (J&J) reported stronger-than-expected 2Q earnings and revenue, driven by robust sales of cancer treatment Darzalex and psoriasis drug Stelara. Revenue of $22.4B surpassed analysts' consensus estimate of $22.3B, with adjusted earnings of $2.82 per share exceeding expectations of $2.70 per share. J&J now expects total 2024 sales of $89.2B to $89.6B, up from its prior forecast of $88.7B to $89.1B.
July 17, 2024
4 Articles